Eric Schmidt


Cowen Chimes in on bluebird bio Inc (BLUE) Following R&D Meeting

Following bluebird bio Inc’s (NASDAQ:BLUE) first research and development (R&D) meeting, Cowen top analyst Eric Schmidt shares insight on the firm’s preclinical strides …

Incyte Corporation (INCY) Epacadostat and Keytruda Could Be Best in Class Immuno-Oncology Combination: Top Analyst

At the European Society for Medical Oncology (ESMO) conference, Incyte Corporation (NASDAQ:INCY) presented updated data from its Phase I trial of epacadostat and …

Cowen Remains Positive on Celgene Corporation (CELG) Following Phase 1B Endoscopy Data

Cowen top analyst Eric Schmidt is out with his commentary on shares of Celgene Corporation (NASDAQ:CELG) after the biotech giant released preliminary data …

Cowen Top Analyst Dives In On Celgene Corporation (CELG) Following Drug Price Hikes

Celegene raised prices for pipeline drugs Revlimid and Pomalyst by 3%

Cowen Top Analyst Cautious on Ionis Pharmaceuticals Inc (IONS); Here’s Why

Ionis Pharmaceuticals Inc (NASDAQ:IONS) posted second-quarter financial results and provided a clinical progress update. Despite many of the drug maker’s pipeline candidates continuing to make …

Cowen Bullish on Exelixis, Inc. (EXEL) In Light Of Early Cabometyx Launch Success

Ever since Exelixis, Inc. (NASDAQ:EXEL) gained approval from the FDA allowing its pipeline drug to be released for treatment of second-line advanced renal …

Celgene Corporation (CELG) Remains Top Pick at Cowen Following Meeting with Management

At a recent dinner with brokerage firm Cowen, CFO Peter Kellogg and Inflammation & Immunology (I&I) President Scott Smith of Celgene Corporation (NASDAQ:CELG) …

This Top Analyst Heads to Sidelines on Merrimack Pharmaceuticals Inc (MACK) as Onivyde Sales Misses Consensus

Merrimack Pharmaceuticals Inc (NASDAQ:MACK) shares are down over 8% this morning, after the cancer drug maker reported second-quarter results, with net Onivyde sales of …

Cowen Top Analyst Bullish on Ionis Pharmaceuticals Inc (IONS) After Infant Muscle Disorder Drug Nusinersen Shines

Yesterday morning, California-based biopharm company Ionis Pharmaceuticals Inc (NASDAQ:IONS) made a positive stride with its clinical drug nusinersen, announcing that major motor milestones were achieved …

Cowen Comments on Sunesis Pharmaceuticals, Inc. (SNSS) Following 2Q:16 Update

Cowen analyst Eric Schmidt weighed in today with a few insights on Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS), after the company reported second-quarter financials and provided investors …

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts